The Efficacy of CD3 x CD19 Bispecific Monoclonal Antibody (BsAb) in a Clonogenic Assay: The Effect of Repeated Addition of BsAb and Interleukin-2

To evaluate the potency by which human T cells are targeted and activated by bispecific monoclonal antibodies (BsAbs) to lyse tumor cells, a clonogenic assay was developed. The efficacy of a CD3xCD19 BsAb binding to both the CD3 T-cell antigen and the CD19 B-cell antigen was already proven in 51Cr-r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 1995-06, Vol.85 (11), p.3208-3212
Hauptverfasser:	Haagen, Inez-Anne, Geerars, Anette J.G., Lau, Wim B.M. de, Bast, Bert J.E.G., Gast, Bert C. de
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Bispecific - immunology Antibodies, Bispecific - pharmacology Antibodies, Bispecific - therapeutic use Antigens, CD - immunology Antigens, CD19 Antigens, Differentiation, B-Lymphocyte - immunology CD3 Complex - immunology Cytotoxicity, Immunologic - drug effects Humans Interleukin-2 - pharmacology Killer Cells, Lymphokine-Activated - drug effects Killer Cells, Lymphokine-Activated - immunology Lymphocyte Activation - drug effects Lymphoma, Non-Hodgkin - immunology Lymphoma, Non-Hodgkin - pathology Lymphoma, Non-Hodgkin - therapy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Recombinant Proteins - pharmacology T-Lymphocyte Subsets - drug effects T-Lymphocyte Subsets - immunology Time Factors Tumor Cells, Cultured - drug effects Tumor Necrosis Factor-alpha - pharmacology Tumor Stem Cell Assay - methods
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!